Millennium's P&L-Based Strategy and the Ortho/J&J Deal

Thanks to a disappointing set of sales numbers and a relatively small upfront fee from its new partner on the recently launched anti-cancer drug, Velcade, investors are once again wondering whether Millennium really has figured out how to be a commercial operation, not a discovery company. But in fact the deal it signed with Johnson & Johnson's Ortho Biotech unit-for ex-US marketing of Velcade is one of several recent signals that the company has focused itself firmly on the new valuation metrics: real earnings growth. The deal structure flies in the face of the most common measures of deal value, and could be as revolutionary in its implications as Millennium's discovery deals had been.

As we go to press, shares in Millennium Pharmaceuticals Inc. are slipping again. Thanks to a disappointing set of sales numbers and a relatively small up-front fee from its new partner on the recently launched anticancer drug bortezomib (Velcade), investors are once again wondering whether the company really has figured out how to be a commercial operation, not a discovery company.

But in fact the deal Millennium signed with Johnson & Johnson 's Ortho Biotech Products LP unit—for ex-US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It

 
• By 

Kura Oncology's new chief medical officer discusses her path to leadership, the company's advancing AML pipeline, and her methodical approach to developing treatments for underserved oncology indications.

Finding The Fire: AltruBio’s Novel Approach To Autoimmune Disease

 
• By 

CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.